person · Reporting owner
Fitzsimons Joseph Francis
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Horizon Quantum Holdings Ltd.HQ · Entity 5127 | Director · Chief Executive Officer · 10% owner | June 12, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Horizon Quantum Holdings Ltd.
Report date June 12, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 10,883 |
Ending reported balance
After 2026-09-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-12 · Exercise / conversion · Acquired 14,321 · Balance 14,321 F1: On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. F2: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. Row 2 · 2026-09-12 · Disposition to issuer · Disposed 3,438 · Balance 10,883 F1: On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. F3: The reported disposition to the Company reflects the settlement in cash of a portion of the RSUs which vested on September 12, 2026, at a price per ordinary share of $15.22, the last reported sales price of the Company's Class A Ordinary Shares on September 11, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 229,148 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Grant · Acquired 229,148 · Balance 229,148 F2: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 214,827 |
Reported balance
After 2026-09-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-12 · Exercise / conversion · Acquired 14,321 · Balance 214,827 F2: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. F1: On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested.
F2: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date.
F3: The reported disposition to the Company reflects the settlement in cash of a portion of the RSUs which vested on September 12, 2026, at a price per ordinary share of $15.22, the last reported sales price of the Company's Class A Ordinary Shares on September 11, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2026 Filed Sep 16, 2026 01:30 UTC | Horizon Quantum Holdings Ltd. HQ · Entity 5127 | Exercise / conversionRestricted Stock Unit · Derivative | 14,321 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-100279 · ownership.xml · derivative · entry 4 Fitzsimons Joseph Francis · CIK 0002122720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,827 Underlying: Class A Ordinary Shares · 14,321 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. F1 · shares: On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. F1 · derivative.exercise_date: On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. F2 · derivative.exercise_date: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. F2 · derivative.expiration_date: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. Read SEC document |
| September 12, 2026 Filed Sep 16, 2026 01:30 UTC | Horizon Quantum Holdings Ltd. HQ · Entity 5127 | Disposition to issuerClass A Ordinary Shares | 3,438 | $15.22 | $52,326.36 |
DisclosureSEC source: 0001213900-26-100279 · ownership.xml · nonDerivative · entry 2 Fitzsimons Joseph Francis · CIK 0002122720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,883 F1 · date: On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. F3 · shares: The reported disposition to the Company reflects the settlement in cash of a portion of the RSUs which vested on September 12, 2026, at a price per ordinary share of $15.22, the last reported sales price of the Company's Class A Ordinary Shares on September 11, 2026. F3 · price: The reported disposition to the Company reflects the settlement in cash of a portion of the RSUs which vested on September 12, 2026, at a price per ordinary share of $15.22, the last reported sales price of the Company's Class A Ordinary Shares on September 11, 2026. Read SEC document |
| September 12, 2026 Filed Sep 16, 2026 01:30 UTC | Horizon Quantum Holdings Ltd. HQ · Entity 5127 | Exercise / conversionClass A Ordinary Shares | 14,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-100279 · ownership.xml · nonDerivative · entry 1 Fitzsimons Joseph Francis · CIK 0002122720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. F1 · shares: On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. F2 · price: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. Read SEC document |
| June 12, 2026 Filed Sep 16, 2026 01:30 UTC | Horizon Quantum Holdings Ltd. HQ · Entity 5127 | GrantRestricted Stock Unit · Derivative | 229,148 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-100279 · ownership.xml · derivative · entry 3 Fitzsimons Joseph Francis · CIK 0002122720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,148 Underlying: Class A Ordinary Shares · 229,148 shares Expires not disclosed F2 · derivative.exercise_price: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. F2 · shares: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. F2 · derivative.exercise_date: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. F2 · derivative.expiration_date: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. F2 · derivative.underlying_shares: On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 24, 2026 22:30 UTC | Horizon Quantum Holdings Ltd. HQ · Entity 5127 | GrantClass B Ordinary Shares | 19,744,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-033688 · ownership.xml · nonDerivative · entry 1 Fitzsimons Joseph Francis · CIK 0002122720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,744,585 F1 · security: Each Class B ordinary share, with no par value (the "Class B Ordinary Shares"), is convertible, at any time, in exchange for one Class A ordinary share, with no par value (the "Class A Ordinary Shares"). F2 · date: Class B Ordinary Shares, received on March 19, 2026, upon the closing of business combination (the "Business Combination") contemplated by the Business Combination Agreement, dated as of September 9, 2025 (the "BCA"), by and among Horizon Quantum Computing Pte. Ltd. ("Legacy Horizon"), dMY Squared Technology Group, Inc., Horizon Quantum Holdings Ltd. (the "Company") and certain other parties, as described in the Registration Statement on Form F-4, as amended and supplemented (File No. 333-292737), initially filed with the U.S. Securities and Exchange Commission on January 14, 2026, and declared effective on February 17, 2026. F3 · price: Pursuant to the BCA and as a result of the Business Combination, Dr. Fitzsimons exchanged his then outstanding 8,108,696 ordinary shares of Legacy Horizon for 19,744,585 Class B Ordinary Shares of the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.